Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Lü, Shun; Wang, Jie; Yu, Yan; Yu, Xinmin; Hu, Yanping; Ai, Xinghao; Ma, Zhiyong; Li, Xingya; Zhuang, Wu; Liu, Yunpeng; Li, Weidong; Cui, Jiuwei; Wang, Dong; Liao, Wangjun; Zhou, Jianying; Wang, Zhehai; Sun, Yuping; Qiu, Xiusong; Gao, Jie; Bao, Yuanyuan; Liang, Liang; Wang, Mengzhao

doi:10.1016/j.jtho.2021.05.005

Public

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Published in Journal of Thoracic Oncology • May 23, 2021

Authors:

Shun Lü

Jie Wang

Yan Yu

Abstract

INTRODUCTION: Tislelizumab, an anti-programmed cell death protein-1 antibody, was specifically engineered to minimize FcɣR macrophage binding to abrogate antibody-dependent phagocytosis. Compared with chemotherapy alone, tislelizumab plus chemotherapy may improve clinical outcomes in patients with a...

Subject

Medicine

Oncology

Chemotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!